+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Stada Arzneimittel AG - Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 49 Pages
  • October 2026
  • GlobalData
  • ID: 5116248
Stada Arzneimittel AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - The analyst’s summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Stada Arzneimittel AG, a subsidiary of Nidda Healthcare GmbH (Stada), is a producer of consumer healthcare, generics, and specialty pharmaceutical products. Its major products include medicines for cough and cold, dermatology, pain and relief, vitamins, minerals, gastric issues, sleep, immunology, nephrology, women's and men's health, bone health, neurology, oncology, ophthalmology, and biosimilars. The company also distributes products of other pharmaceutical companies. It offers products to a wide range of customers and patients through brands such as Nizoral, Zoflora, Grippostad, SNUP, Silomat, and Hirudoid, among others, in Asia, the Middle East, and Europe. Stada is headquartered in Bad Vilbel, Hessen, Germany.

Stada Arzneimittel AG Key Recent Developments

  • Sep 28, 2026: STADA and SBP Group Launch Strategic Biosimilars Partnership Including Pembrolizumab Biosimilar
  • Sep 09, 2026: STADA Pymepharco Ho Chi Minh City Office to Relocate
  • Sep 07, 2026: STADA Appoints Diana Wiedmann as Chief Culture and People Officer
  • Jul 01, 2026: STADA Welcomes Former Reckitt Executive Mark Pearson as Global Head Consumer Healthcare

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with the analyst’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Stada Arzneimittel AG - Key Facts
  • Stada Arzneimittel AG - Key Employees
  • Stada Arzneimittel AG - Key Employee Biographies
  • Stada Arzneimittel AG - Major Products and Services
  • Stada Arzneimittel AG - History
  • Stada Arzneimittel AG - Company Statement
  • Stada Arzneimittel AG - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Stada Arzneimittel AG - Business Description
  • Business Segment: Consumer Healthcare
  • Overview
  • Performance
  • Business Segment: Generics
  • Overview
  • Performance
  • Business Segment: Specialty Pharmaceuticals
  • Overview
  • Performance
  • R&D Overview
  • Stada Arzneimittel AG - Corporate Strategy
  • Stada Arzneimittel AG - SWOT Analysis
  • SWOT Analysis - Overview
  • Stada Arzneimittel AG - Strengths
  • Stada Arzneimittel AG - Weaknesses
  • Stada Arzneimittel AG - Opportunities
  • Stada Arzneimittel AG - Threats
  • Stada Arzneimittel AG - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Stada Arzneimittel AG, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • Sep 28, 2026: STADA and SBP Group Launch Strategic Biosimilars Partnership Including Pembrolizumab Biosimilar
  • Sep 09, 2026: STADA Pymepharco Ho Chi Minh City Office to Relocate
  • Sep 07, 2026: STADA Appoints Diana Wiedmann as Chief Culture and People Officer
  • Jul 01, 2026: STADA Welcomes Former Reckitt Executive Mark Pearson as Global Head Consumer Healthcare
  • May 04, 2026: STADA Strengthens Consumer Healthcare Portfolio by Acquiring Locobase
  • May 04, 2026: STADA Strengthens as a Leader in Consumer Healthcare
  • May 04, 2026: STADA Strengthens Position in European Consumer Healthcare
  • Apr 07, 2026: STADA Pymepharco Names Ankur Pandey as CEO
  • Mar 30, 2026: STADA Signs Agreement With CuraTeQ for Neutropenia Biosimilars in Europe
  • Feb 16, 2026: STADA Invests More Than €85m in Saudi Arabia Manufacturing Hub
Section 5 - Appendix
  • Methodology
  • About the Analyst
  • Contact Us
  • Disclaimer
List of Tables
  • Stada Arzneimittel AG, Key Facts
  • Stada Arzneimittel AG, Key Employees
  • Stada Arzneimittel AG, Key Employee Biographies
  • Stada Arzneimittel AG, Major Products and Services
  • Stada Arzneimittel AG, History
  • Stada Arzneimittel AG, Other Locations
  • Stada Arzneimittel AG, Subsidiaries
  • Stada Arzneimittel AG, Key Competitors
  • Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Stada Arzneimittel AG, Recent Deals Summary
List of Figures
  • Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • MPA Pharma GmbH
  • Teva Pharmaceutical Industries Ltd
  • MorphoSys AG
  • Bayer AG
  • Sandoz Group AG
  • Reckitt Benckiser Group Plc
  • MediGene AG
  • Laboratorios Cinfa SA
  • Evotec SE
  • EGIS Pharmaceuticals Plc
  • Fresenius Kabi AG
  • Aurobindo Pharma Ltd
  • Sanofi
  • Les Laboratoires Servier SAS
  • Laboratorios Normon SA
  • Kenvue Inc
  • Biotest GmbH & Co KGaA
  • Zentiva SA
  • Haleon Plc
  • Viatris Inc